Study guide
13.3 Quality Improvement, Risk Management, and Workplace Safety
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
13.3 Quality Improvement, Risk Management, and Workplace Safety
Key Takeaways Explain This Topic AI
Continuous quality improvement uses the Plan-Do-Study-Act cycle to test a change on a small scale before spreading it.
Root cause analysis is retrospective and asks why an incident happened; failure mode and effects analysis is prospective and asks what could fail before it does.
Risk management follows a defined cycle of identification, assessment by likelihood and severity, control, and review, with elimination and engineering controls preferred over reliance on individual vigilance.
WHMIS 2015 aligns Canadian hazard communication with the Globally Harmonized System, requiring standardised labels, pictograms, and safety data sheets with 16 sections.
Employers have a duty to protect workers from workplace violence and harassment, and every worker has the right to know, the right to participate, and the right to refuse unsafe work.
Last updated: August 2026
13.3 Quality Improvement, Risk Management, and Workplace Safety
Exam Focus: Quality improvement, risk management, and workplace safety are three of the six elements listed under pharmacy management in the blueprint. Items test the difference between prospective and retrospective analysis, the hierarchy of controls, and workers' statutory rights.
Continuous Quality Improvement
Most Canadian jurisdictions now require community pharmacies to operate a documented continuous quality improvement (CQI) program : recording medication incidents and near misses, analysing them for contributing factors, implementing changes, sharing learning, and reviewing the program periodically. Anonymised reporting to a national system supports learning beyond the individual pharmacy.
The core method is the Plan-Do-Study-Act (PDSA) cycle :
- Phase Activity
- Plan Define the objective and the measure, predict the result, and plan the test
- Do Run the test on a deliberately small scale and record what happened, including the unexpected
- Study Compare the result against the prediction and identify what was learned
- Act Adopt, adapt, or abandon — then run the next cycle
The discipline of PDSA is the small scale. Testing a new label check with one pharmacist for one day surfaces the practical problems before the change is imposed on the whole team.
Improvement requires measurement. Distinguish outcome measures (did harm fall), process measures (is the new step actually being done), and balancing measures (did the change create a new problem elsewhere, such as longer wait times).
Analysing Incidents
Method Direction Question When used
Root cause analysis (RCA) Retrospective Why did this happen? After a serious incident or a significant near miss
Failure mode and effects analysis (FMEA) Prospective What could go wrong, how likely is it, and how bad would it be? Before introducing a new process, product, or technology
A root cause analysis follows a structure: assemble a multidisciplinary team, construct a factual timeline, ask "why" repeatedly to move past the proximate cause, identify contributing system factors, and generate corrective actions with owners and dates. The finding "the pharmacist was distracted" is a proximate cause, not a root cause; the root cause is whatever made distraction likely and undetectable.
A failure mode and effects analysis scores each potential failure for severity, likelihood of occurrence, and likelihood of detection, multiplies them into a risk priority number, and directs effort at the highest scores.
The hierarchy of effectiveness applies to both. Ranked from most to least effective:
Forcing functions and constraints — the unsafe action becomes impossible, such as removing concentrated potassium chloride from ward stock.
Automation and computerisation — with the caveat that automation introduces new failure modes.
Standardisation and protocols — one agreed way of doing the task.
Independent double checks — useful but limited by confirmation bias.
Rules and policies.
Education and information.
Being more careful — the least effective, and the most commonly proposed.
An action plan consisting only of "staff were reminded" is a failed analysis.
Risk Management
Risk management is the systematic identification and control of anything that could harm patients, staff, or the organisation. The cycle is: identify, assess, control, and review .
Assessment plots each risk by likelihood and severity so that finite effort goes to the risks that matter most. Controls follow the same hierarchy as above: eliminate the hazard, substitute something safer, apply engineering controls such as a containment cabinet, apply administrative controls such as a policy or training, and only then rely on personal protective equipment .
For a community pharmacy the recurring risk categories are clinical (dispensing error, missed interaction, incorrect compounding), operational (system failure, supply disruption, cold-chain excursion), financial (fraud, uncollected receivables, audit recovery), and reputational and legal (privacy breach, professional misconduct complaint).
Professional liability insurance is required by most regulatory authorities and covers the individual pharmacist as well as the employer. Insurance transfers financial risk; it does not transfer professional accountability. Notify the insurer early when an incident may lead to a claim, document contemporaneously, and never alter a record after the fact — a corrected entry is made as a new dated note, never by overwriting the original.
Workplace Safety in the Pharmacy
Occupational health and safety in Canada is primarily provincial or territorial, with federal jurisdiction over federally regulated workplaces. Three worker rights are common to every jurisdiction:
The right to know about hazards in the workplace.
The right to participate in health and safety through a committee or representative.
The right to refuse work the worker reasonably believes to be dangerous, without reprisal.
The employer holds a general duty to take every reasonable precaution to protect workers, and supervisors and workers hold corresponding duties.
Hazard communication: WHMIS 2015
The Workplace Hazardous Materials Information System was aligned with the Globally Harmonized System of Classification and Labelling of Chemicals. It has three elements: standardised labels with a product identifier, hazard pictograms, signal words ("Danger" or "Warning"), hazard and precautionary statements, and supplier identification; safety data sheets in a fixed 16-section format; and worker education and training . Safety data sheets must be readily accessible to workers for every hazardous product used in the pharmacy.
Hazardous drugs
Hazardous drugs — cytotoxics and other agents that are carcinogenic, teratogenic, or toxic to reproduction — require a documented handling program: a current list of hazardous products, receipt and storage procedures, negative-pressure containment for preparation, closed-system transfer devices where indicated, defined personal protective equipment, spill kits with trained responders, and safe disposal. Counting hazardous tablets on the general counting tray, or crushing them, contaminates the workspace. Staff who are pregnant, breastfeeding, or trying to conceive should be able to request alternative duties without penalty.
Other pharmacy hazards
Needlestick and sharps injuries — safety-engineered devices, no recapping, point-of-use disposal, and an immediate reporting and post-exposure protocol.
Infectious disease exposure — routine practices, hand hygiene, respiratory etiquette, appropriate personal protective equipment, and immunization of staff.
Ergonomics — repetitive strain from data entry and counting, prolonged standing, and poor workstation height; addressed with anti-fatigue matting, adjustable workstations, and job rotation.
Workplace violence and harassment — employers must have a written program with risk assessment, reporting procedures, and training. Pharmacies are exposed through cash handling, controlled substance stock, and conflict at the counter. Practical controls include sightlines, panic alarms, limited controlled substance stock, lone-working procedures, and de-escalation training.
Fatigue and workload — long shifts without breaks measurably increase error rates, making break scheduling and workload management a safety control rather than a courtesy.